• RedHill Biopharma divested its Talicia business to an Apotex subsidiary for USD 18 million cash upfront.
• Deal includes up to USD 35 million in potential payments tied to worldwide net sales milestones.
• Apotex will acquire RedHill’s 70% interest in Talicia, consolidating ownership following its prior purchase of Cumberland’s 30% stake.
• Proceeds earmarked to fund a strategic shift toward larger commercial product opportunities and support an accelerated path to operational profitability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via CNW (Ref. ID: 202608310700CANADANWCANADAPR_C8636) on August 31, 2026, and is solely responsible for the information contained therein.